Rodriguez-Arnao M D, Peters J R, Foord S M, Dieguez C, Edwards C, Gomez-Pan A, Hall R, Newcombe R G, Scanlon M F
J Clin Endocrinol Metab. 1983 Nov;57(5):975-80. doi: 10.1210/jcem-57-5-975.
In order to delineate more accurately the dopaminergic control of anterior pituitary function in normal subjects and in patients with pathological hyperprolactinemia, we investigated the nature of the circadian variation in the dopaminergic inhibition of TSH release in such subjects. Ten euthyroid women with hyperprolactinemia due to presumed PRL-secreting microadenomas (aged 18-60 yr) were compared with 11 normal, euthyroid women (aged 18-32 yr). Each received the dopamine receptor blocking drug domperidone (10 mg, iv) at 1100 and 2300 h (tests randomized and separated by at least 1 week). Blood was sampled 10, 20, 30, 45, and 60 min after drug administration. Normal women had a greater TSH response to domperidone and, hence, greater dopaminergic inhibition of TSH release at 2300 than at 1100 h (sum of TSH increments; mU/liter mean +/- SE, 8.5 +/- 1.3 vs. 4.8 +/- 0.5, P less than 0.01), whereas there was no difference in the dopaminergic inhibition of PRL release at each time of day. Hyperprolactinemic women also had a significantly greater TSH response to domperidone at 2300 than at 1100 h (42.0 +/- 10.2 vs. 19.1 +/- 2.8, P less than 0.001). The hyperprolactinemic women had a greater TSH response to domperidone than normal women at each time of day studied (1100 h, 19.1 +/- 2.8 vs. 4.8 +/- 0.5, P less than 0.001; 2300 h, 42.0 +/- 10.2 vs. 8.5 +/- 1.3, P less than 0.001). The incremental PRL responses to domperidone were significantly less in hyperprolactinemic than in normal women and did not differ at each time of day. In conclusion, the circadian change in the dopaminergic inhibition of TSH secretion is specific for TSH and not PRL. This indicates that the dopaminergic control of TSH and PRL secretion can be dissociated in normal subjects. Second, hyperprolactinemic women with presumed PRL-secreting microadenomas had qualitatively normal but quantitatively exaggerated circadian pattern of dopaminergic inhibition of TSH release. These data argue against a hypothalamic dopaminergic defect in hyperprolactinemia and support the view that the established dopaminergic defect in the inhibition of PRL release is related specifically to PRL control and may well be at the anterior pituitary level.
为了更准确地描述正常受试者和病理性高催乳素血症患者垂体前叶功能的多巴胺能控制情况,我们研究了此类受试者中多巴胺能对促甲状腺激素(TSH)释放的昼夜变化性质。将10名因推测为分泌催乳素(PRL)的微腺瘤导致高催乳素血症的甲状腺功能正常女性(年龄18 - 60岁)与11名正常的甲状腺功能正常女性(年龄18 - 32岁)进行比较。每位受试者在上午11点和晚上11点接受多巴胺受体阻断药物多潘立酮(10毫克,静脉注射)(测试随机进行,间隔至少1周)。给药后10、20、30、45和60分钟采集血样。正常女性对多潘立酮的TSH反应更大,因此,晚上11点时多巴胺能对TSH释放的抑制作用比上午11点时更强(TSH增量总和;mU/升,平均值±标准误,8.5±1.3对4.8±0.5,P<0.01),而在一天中的每个时间点,多巴胺能对PRL释放的抑制作用没有差异。高催乳素血症女性晚上11点时对多潘立酮的TSH反应也明显大于上午11点时(42.0±10.2对19.1±2.8,P<0.001)。在所研究的一天中的每个时间点,高催乳素血症女性对多潘立酮的TSH反应都比正常女性更大(上午11点,19.1±2.8对4.8±0.5,P<0.001;晚上11点,42.0±10.2对8.5±1.3,P<0.001)。高催乳素血症女性对多潘立酮的PRL增量反应明显小于正常女性,且在一天中的每个时间点没有差异。总之,多巴胺能对TSH分泌的抑制作用的昼夜变化是TSH特有的,而非PRL。这表明在正常受试者中,多巴胺能对TSH和PRL分泌的控制可以分离。其次,因推测为分泌PRL的微腺瘤导致高催乳素血症的女性,其多巴胺能对TSH释放的抑制作用的昼夜模式在性质上正常,但在数量上有所夸大。这些数据反对高催乳素血症中存在下丘脑多巴胺能缺陷的观点,并支持以下观点:在抑制PRL释放方面已确定的多巴胺能缺陷与PRL控制特异性相关,很可能发生在垂体前叶水平。